**Progyny Seesaws Amid Confusion Over Impact from Trump’s IVF Initiative**
*October 17, 2025 – 1:11 PM ET*
Progyny, Inc. experienced significant volatility following the Trump administration’s announcement of a new initiative aimed at expanding access to in vitro fertilization (IVF). This move coincided with a major drug pricing agreement involving fertility treatment manufacturer EMD Serono, a subsidiary of Merck KGaA.
The announcement has generated mixed reactions and uncertainty about how it will affect Progyny’s market position and stock performance. Investors are closely monitoring the situation as the company navigates these developments.
**Stock Snapshot:**
– **Symbol:** PGNY
– **Previous Close:** —
– **Short Interest:** —
Stay tuned for more updates and analysis on Progyny and the broader fertility treatment sector as this story unfolds.
https://seekingalpha.com/news/4505299-progyny-down-amid-confusion-trumps-ivf-initiative?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
